The Fourth Transatlantic Exchange in Oncology: Radiopharmaceutical Therapy Meets Oncology

Wednesday, March 19, 2025 | 10:00 CET

Hyatt Regency Paris Étoile
PARIS, FRANCE

OVERVIEW

With novel radiopharmaceutical therapies entering clinical trials and into clinical practice, the 2025 Transatlantic Exchange in Oncology will focus on bringing together key experts from Boston, USA and Paris, France to highlight the latest advances in the application of these targeted agents for oncology. The 1-day event will deliver a comprehensive overview of this highly competitive and dynamic area within the R&D landscape, enabling attendees to understand cutting-edge research as well as the challenges in bringing these therapies to routine clinical application.

Faculty

agenda

March 19, 2025

10:00 – 10:20 AM | Opening and Welcome Toni K. Choueiri, MD (Program Chair, Moderator)
Karim Fizazi, MD, PhD (Program Chair, Moderator)
Kevin Haigis, PhD
Fabrice Barlesi, MD, PhD
Patrick Therasse, MD, PhD

10:20 – 11:50 AM | Session 1
Precision Oncology & Molecular Imaging: Early Detection and Characterization

Fabrice Barlesi, MD, PhD (Moderator)
Toni K. Choueiri, MD (Moderator)

Antibody-Based Radiotheranostics for Tumor Characterization and Therapy
Fay Nicolson, PhD

Advances in Genitourinary Cancers (Lessons Learned From PSMA)
Ronan Flippot, MD

The Model of Breast Cancer: From In Vivo Target to Diagnostic Radiopharmaceutical
Théophraste Henry, PhD

Using Imaging to Test Tumor Biology and Heterogeneity
Himisha Beltran, MD

Session includes 15-min Q&A and 15-min break

11:50 – 12:30 PM | Keynote Address Fabrice André, MD, PhD (Moderator)
Heather Jacene, MD (Moderator)

Seeing Beyond VISION: Designing RLT Trials That Yield a Survival Benefit
Michael J. Morris, MD, FASCO

Session includes a 10-min Q&A

12:30 – 14:30 | Session 2
How to Go From Non-Radiolabeled Target to a Radiolabeled Active Product

Toni K. Choueiri, MD (Moderator)
Patrick Therasse, MD, PhD (Moderator)

Are My Target and Probe Suitable for Radiolabeling?
Mohammad Rashidian, PhD

Developing Targeted Alpha Therapeutics: Heartbreak or Happily Ever After?
Anthony P. Belanger, PhD

The Radiolabeled ADC: The Pharmaceutical Challenges
Angelo Paci, PharmD, PhD

The First in Human: How to Deal With Phase I Studies
Christophe Massard, MD, PhD

Session includes 15-min Q&A and 15-min break

14:30 - 16:15 – | Session 3
Future Directions and Latest Clinical Applications

Karim Fizazi, MD, PhD (Moderator)
Heather Jacene, MD (Moderator)

Monitoring and Tumor Assessment Post-Radioligand Therapy
Praful Ravi, MB, BChir, MRCP

Strategies to Target the Immune System With Radiolabeled Antibodies
Bertrand Kuhnast, PhD

The Impact of Molecular Profile on Response to Treatment: The UNLOCK Program
Yohann Loriot, MD, PhD

Radiopharmaceuticals in Heme Malignancies: Waldenström Macroglobulinemia
Jorge J. Castillo, MD

Radioconjugates Using Small Linear Peptides
Kevin Lee, PhD, MBA

Session includes 15-min Q&A and 15-min break

16:15 – 17:15 | Session 4
Radioligand Therapies: Academia and Industry Perspectives

Désirée Deandreis, MD (Moderator)
Leonhard Schaetz, MD (Moderator)

Radiopharmaceuticals – It Is All About Compromises
Amal Saidi, PhD

Challenges in Scaling Up Facilities
Désirée Deandreis, MD

Industry Perspective: Scaling Up Radio-DARPin Platform: Experience of Two European Biotech Partners - Molecular Partners and Orano Med
Michael Stumpp, PhD
Amal Saidi, PhD 

Session includes 15-min Q&A and 15-min break

17:15 - 17:30 | Closing Remarks
Chairs to Close

Toni K. Choueiri, MD (Program Chair, Moderator)
Karim Fizazi, MD, PhD (Program Chair, Moderator)